Clinical trial • Phase I • Oncology
225Ac-PSMA I&T for Metastatic prostate cancer
Phase I trial of 225Ac-PSMA I&T for Metastatic prostate cancer. None/Not specified-controlled. 30 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic prostate cancer
- Trial Stage
- Phase I
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 05-09-2024
- First CTIS Authorization Date
- 24-09-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 30
Eligibility
Recruits 30 Vulnerable populations not selected; no information on consent or assent handling provided..
- Vulnerable Population
- Vulnerable populations not selected; no information on consent or assent handling provided.
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 45
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Netherlands
- Earliest CTIS Part Ii Submission Date
- 18-09-2024
- Latest Decision Or Authorization Date
- 24-09-2024
- Processing Time Days
- 6
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Radiology and Nuclear Medicine
- Contact Person Name
- Tessa Brabander
- Contact Person Email
- t.brabander@erasmusmc.nl
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- 225Ac-PSMA I&T
- Active Substance
- 225Ac-PSMA I&T
- Modality
- Radiopharmaceutical
Related trials
Other published trials that may interest you.